INNER MONGOLIA FURUI MEDICAL SCIENCE CO., LTD. Inner Mongolia Furui Medical Science Co., Ltd. Stock
Equities
300049
CNE100000KG1
Advanced Medical Equipment & Technology
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 50.2 CNY | +1.93% |
|
+1.56% | +15.16% |
| Sales 2024 * | 1.58B 219M | Sales 2025 * | 2.16B 298M | Capitalization | 13.21B 1.82B |
|---|---|---|---|---|---|
| Net income 2024 * | 203M 28.03M | Net income 2025 * | 307M 42.4M | EV / Sales 2024 * | 8.34 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 6.12 x |
| P/E ratio 2024 * |
64.6
x | P/E ratio 2025 * |
44.5
x | Employees | 703 |
| Yield 2024 * |
0.59% | Yield 2025 * |
1.08% | Free-Float | 67.87% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.93% | ||
| 1 week | +1.56% | ||
| 1 month | -1.57% | ||
| 3 months | +14.12% | ||
| 6 months | +20.53% | ||
| Current year | +15.16% |
1 week
48.84
51.16
1 month
48.8454.83
Current year
28.7357.50
1 year
20.3457.50
3 years
9.9457.50
5 years
6.6757.50
10 years
6.6774.94
| Managers | Title | Age | Since |
|---|---|---|---|
Guan Yi Wang
CEO | Chief Executive Officer | 54 | 98-10-31 |
Xiu Zhen Sun
DFI | Director of Finance/CFO | 53 | 07-12-31 |
Li Juan Deng
BRD | Director/Board Member | 60 | 20-05-19 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Guan Yi Wang
CEO | Chief Executive Officer | 54 | 98-10-31 |
Li Qun Wang
CHM | Chairman | 56 | 03-08-31 |
Yong Yang
BRD | Director/Board Member | 54 | 20-05-19 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 50.2 | +1.93% | 2,638,800 |
| 24-05-30 | 49.25 | -1.62% | 2,525,100 |
| 24-05-29 | 50.06 | -0.34% | 2,087,153 |
| 24-05-28 | 50.23 | -1.51% | 2,182,400 |
| 24-05-27 | 51 | +3.18% | 3,897,879 |
End-of-day quote Shenzhen S.E., May 30, 2024
More quotes
Inner Mongolia Furui Medical Science Co., Ltd is a China-based company principally engaged in the diagnosis and treatment of hepatic fibrosis. The Company is mainly engaged in the manufacture and sale of medicines, the research, development and sale of diagnostic equipment, as well as the provision of related services. The Companyâs main products include Fufang Biejia Ruangan talbets, Kezhi capsules and instantaneous elastic imaging equipment FibroScan. The Company distributes its products in domestic market and to overseas markets.
Calendar
2024-08-29
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
50.2
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +15.16% | 1.82B | |
| -27.52% | 16.33B | |
| -40.04% | 2.96B | |
| -6.86% | 1.55B | |
| +38.67% | 1.41B | |
| -15.36% | 976M | |
| +3.53% | 811M | |
| -26.08% | 846M | |
| +23.58% | 593M | |
| -24.63% | 631M |
- Stock Market
- Equities
- 300049 Stock
